Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice

Journal of Experimental Therapeutics and Oncology

Volumn 3, Issue 2, 2003, Pages 72-82

  Lopes de Menezes, Daniel E ^a   Hu, Yanping ^a   Mayer, Lawrence D ^a,b,c  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Celator Technologies Inc   (Canada)

Author keywords

Bcl 2 antisense; Breast cancer; Doxorubicin; Drug resistance; Liposomes; P glycoprotein; PSC833

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CISPLATIN; DOXORUBICIN; LIPOSOME; OBLIMERSEN; PACLITAXEL; PROTEIN BCL 2; PROTEIN INHIBITOR; VALSPODAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG RETENTION; DRUG SENSITIVITY; FEMALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYCLOSPORINS; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE THERAPY; HUMANS; INHIBITORY CONCENTRATION 50; LIPOSOMES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; P-GLYCOPROTEIN; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0038792322     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1359-4117.2003.01075.x     Document Type: Article

References (34)

1. Giaccone G, Linn SC, Pinedo HM. Multidrug resistance in breast cancer: mechanisms, strategies. Eur J Cancer 31A (suppl 7): 15-17, 1995.
2. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
3. Ling V. P-Glycoprotein and resistance to anticancer drugs. Cancer 69: 2603-2609, 1992.
4. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer 32A: 921-926, 1996.
5. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T. Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60: 23-32, 1996.
6. Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur J Cancer 27: 155-158, 1991.
7. Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 60: 815-818, 1989.
8. Ford JM, Halt WN. Pharmacology of drugs that alter multidrug resistance in Cancer. Pharmacol Rev 42: 155-199, 1990.
9. Drori S, Eytan GD, Assaraf YG. Potentiation of anticancer drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 228: 1020, 1995.
10. Boesch D, Gavriaux C, Jachez B, Pourtier-Mnzanedo A, Bollinger P, Loor F. In-vivo circumvention of P-glycoprotein mediated multidrug resistance of tumor cells with PSC833. Cancer Res 51: 4226, 1991.
11. Watanabe T, Tsuge H, Oh-hara T, Naito M, Tsuruo T. Comparative study on reversal efficacy of SDZ PSC833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34: 235, 1995.
12. Krishna R, St-Lous M, Mayer L. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC833) with sterically stabilized liposomal doxorubicin. Int J Cancer 85: 131-141, 2000.
13. Lum B, Gosland M. MDR expression in normal tissues: Pharmacologic implications for the clinical use of P-glycoprorein inhibitors. Hematol Oncol Clin North Am 9: 319, 1995.
14. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460-11464, 1991.
15. Gabizon A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 52: 891, 1992.
16. Yuan F, Leuning M, Huang SK, Berk DA, Papahajopoulos D, Jain RK. Microvascular permeability of interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54: 3352-3356, 1994.
17. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 11: 68-75, 1999.
18. Webb SJ, Harrison DJ, Wylie AH. Apoptosis: an overview of the process and its relevance in disease. In: Kaufmaann S, ed. Apoptosis, Pharmacological Implications and Therapeutic Opportunities. London: Academic Press, 1-34. 1997.
19. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in human leukemia cell line. Blood 81: 151-157, 1993.
20. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9: 451-473, 1995.
21. Wintersberger U. Ribonucleases H of retroviral and cellular origin. Pharmacol Ther 48: 259-280, 1990.
22. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z. Bcl-2 antisense therapy in patients with non-Hodgkin's lymphoma. Lancet 349: 1137-1141, 1997.
23. Jansen B, Schlagbauer-Wadi H, Brown BD, et al. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4: 232-234, 1998.
24. Jansen B, Wacheck V, Heere-Rees E, et al. Chemosensitization of malignant melanoma by Bcl-2 antisense therapy. Lancet 356: 1728-1733, 2000.
25. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FMP. Eradication of human non-Hodgkin's lymphoma in SCID mice by Bcl-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6: 2492-2500, 2000.
26. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD. Molecular and pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotides G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 6: 2891-2902, 2000.
27. Derksen JTP, Moselt HWM, Scherphof GL. Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages. Biochim Biophys Acta 931: 33-40, 1987.
28. Mayer LD, Hope MJ, Cullis PR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 858: 161-168, 1986.
29. Mayer LD, Bally MB, Cullis PR. Uptake of Adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857: 123-126, 1986.
30. Shabbits JA, Mayer LD. P-Glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther 1: 205-213, 2002.
31. Chi KN, Wallis AE, Lee CH, Lopez de Menezes DE, Sarton J, Dragowska WH, Mayer LD. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat 1750: 1-14, 2000.
32. Dedhar S, Hannigan GE, Rak J, Kerbel RS. The extracellular environment and cancer. In: Tannock IF, Hill RP, eds. The Basic Science of Oncology, 3rd edition. New York: McGraw-Hill, 198-218, 1998.
33. Hu XF, Slater A, Wall DM, Parkin JD, Kantharidis P, Zalberg JR. Cyclosporin A and PSC833 prevent up-regulation of MDR1 expression by anthracyclines in human multidrug-resistant cell line. Clin Cancer Res 2: 713-720, 1996.
34. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspases-dependent apoptosis. Proc Natl Acad Sci USA 95: 7024-7029, 1998.